Department of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
Zhendong Research Institute, Shanxi-Zhendong Pharmaceutical Co Ltd, Beijing, China.
PLoS One. 2020 Jul 30;15(7):e0236395. doi: 10.1371/journal.pone.0236395. eCollection 2020.
Traditional Chinese Medicine (TCM) preparations are often extracts of single or multiple herbs containing hundreds of compounds, and hence it has been difficult to study their mechanisms of action. Compound Kushen Injection (CKI) is a complex mixture of compounds extracted from two medicinal plants and has been used in Chinese hospitals to treat cancer for over twenty years. To demonstrate that a systematic analysis of molecular changes resulting from complex mixtures of bioactives from TCM can identify a core set of differentially expressed (DE) genes and a reproducible set of candidate pathways. We used in vitro cancer models to measure the effect of CKI on cell cycle phases and apoptosis, and correlated those phenotypes with CKI induced changes in gene expression. We treated two cancer cell lines with or without CKI and assessed the resulting phenotypes by employing cell viability and proliferation assays. Based on these results, we carried out high-throughput transcriptome data analysis to identify genes and candidate pathways perturbed by CKI. We integrated these differential gene expression results with previously reported results and carried out validation of selected differentially expressed genes. CKI induced cell-cycle arrest and apoptosis in the cancer cell lines tested. In these cells CKI also altered the expression of 363 core candidate genes associated with cell cycle, apoptosis, DNA replication/repair, and various cancer pathways. Of these, 7 are clinically relevant to cancer diagnosis or therapy, 14 are cell cycle regulators, and most of these 21 candidates are downregulated by CKI. Comparison of our core candidate genes to a database of plant medicinal compounds and their effects on gene expression identified one-to-one, one-to-many and many-to-many regulatory relationships between compounds in CKI and DE genes. By identifying genes and promising candidate pathways associated with CKI treatment based on our transcriptome-based analysis, we have shown that this approach is useful for the systematic analysis of molecular changes resulting from complex mixtures of bioactives.
中药(TCM)制剂通常是由一种或多种草药的提取物组成,其中含有数百种化合物,因此很难研究其作用机制。复方苦参注射液(CKI)是从两种药用植物中提取的化合物的复杂混合物,在中国医院中已用于治疗癌症超过二十年。为了证明对来自中药的生物活性复杂混合物的分子变化进行系统分析可以鉴定出一组差异表达(DE)基因和一组可重复的候选途径。我们使用体外癌症模型来测量 CKI 对细胞周期相和细胞凋亡的影响,并将这些表型与 CKI 诱导的基因表达变化相关联。我们用 CKI 处理或不处理两种癌细胞系,并通过细胞活力和增殖测定来评估由此产生的表型。基于这些结果,我们进行了高通量转录组数据分析,以鉴定受 CKI 干扰的基因和候选途径。我们将这些差异基因表达结果与先前报道的结果整合在一起,并对选定的差异表达基因进行了验证。CKI 在测试的癌细胞系中诱导细胞周期停滞和细胞凋亡。在这些细胞中,CKI 还改变了与细胞周期,细胞凋亡,DNA 复制/修复以及各种癌症途径相关的 363 个核心候选基因的表达。其中,有 7 个与癌症诊断或治疗有关,14 个是细胞周期调节剂,而这些 21 个候选基因中的大多数都被 CKI 下调。将我们的核心候选基因与植物药用化合物数据库及其对基因表达的影响进行比较,确定了 CKI 化合物与 DE 基因之间的一对一,一对多和多对多的调控关系。通过基于转录组的分析确定与 CKI 治疗相关的基因和有前途的候选途径,我们已经表明,这种方法对于系统分析来自生物活性复杂混合物的分子变化是有用的。